Conversion Surgery Following Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma with Para-Aortic Lymph Node Metastases: A Case of Complete Hepatic Response and Lymphatic Resistance
This case demonstrates a discrepant therapeutic response, with a pCR in the liver contrasted with residual undifferentiated carcinoma in the PALNs. To our knowledge, this is the first reported HCC case demonstrating hepatic pCR after ICI therapy with residual undifferentiated carcinoma confined to the PALNs, highlighting immune-resistant extrahepatic clones and the diagnostic-therapeutic value of conversion surgery.
Authors
- Takehiro Okabayashi
- Jun Iwata
- Teppei Tokumaru (ORCID: https://orcid.org/0000-0003-4423-2359)
- Rika Yoshimatsu (ORCID: https://orcid.org/0009-0004-6273-0022)
- Manabu Matsumoto
- Sunao Uemura (ORCID: https://orcid.org/0000-0001-7299-0152)
- Shuta Tamura
- Shinya Sakamoto
- Motoyasu Tabuchi
Institutions
- CHI Health (US)
Publication Details
- Journal
- Surgical Case Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.70352/scrj.cr.25-0539
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00